Nolan Williams
Stanford Brain Stimulation Lab
Nolan Williams is a neuropsychiatrist and the Director of the Stanford Brain Stimulation Lab. His published research focuses on neuromodulation interventions, including transcranial magnetic stimulation, deep brain stimulation, and Stanford Neuromodulation Therapy (SAINT) for disorders such as treatment-resistant depression and obsessive-compulsive disorder. Additionally, he studies the neural correlates and therapeutic outcomes of magnesium-ibogaine treatments for post-traumatic stress disorder and traumatic brain injury.
32 claims checked on air: 2 context 3 overstated 23 supported 4 unverified
What they said on air - overstated
5 citing their own research
In a study of veterans undergoing ibogaine treatment, participants exhibited a sustained reduction in alcohol consumption that approached zero despite not seeking treatment for alcohol use.
"So, our data, we we also collected alcohol use. Um, and what we found was, and we're going to publish this soon, that uh people's alcohol use really precipitously dropped almost close to to zero. And so just almost everybody just really dramatic improvements in alcohol um and uh and maintained it." (said at 0:40:39)
While prospective observational data on Special Operations Forces Veterans receiving combined ibogaine and 5-MeO-DMT treatment showed a statistically significant reduction in alcohol misuse scores through 6 months post-treatment, the claim overstates the magnitude of effect and proportion of participants who benefited. Rather than alcohol use dropping 'almost close to zero' for 'almost everybody', only 24% of veterans with baseline risky drinking achieved total abstinence at 1 month (16% at 6 months), and 53% remained risky drinkers at 6 months. Additionally, these open-label observational findings lack a control group.
- partial: Prospective associations of psychedelic treatment for co-occurring alcohol misuse and post… (Military psychology : the official journal of the Division of Military Psychology, American Psychological Association 2024) · cited 19x in the literature
"There was a significant reduction in alcohol use from pre-treatment (M = 7.2, SD = 2.3) to 1 m (M = 3.6; SD = 3.5) post-treatment, which remained reduced through 6 m (M = 4.0; SD = 2.9; p < .001, partial eta squared = .617). At 1 m, 24% were abstinent, 33% were non-risky drinking, and 42% were risky drinkers. At 6 m, 16% were abstinent, 31% were non-risky drinking, and 53% were risky drinkers." (abstract, results, passage verified)
pubmedfull study (doi)
Survivors of the October 7th festival attack in Israel who were under the influence of MDMA exhibited a statistically significantly lower incidence of PTSD onset compared to those who were not.
"There's an analysis of the, you know, events that happened in Israel with the with the rave, right? And in that situation, there was a certain percentage of those people that were actually on MDMA. I don't know if you know about that. ... They actually saw a statistically significantly lower PTSD onset in individuals that were on MDMA compared to people that weren't for that experience" (said at 0:54:15)
Studies examining survivors of the October 7, 2023 Nova festival attack who were under the influence of psychoactive substances (including MDMA/empathogens and classic psychedelics) have explored peritraumatic experiences and psychological outcomes. Preliminary mixed-methods and observational survey data suggest that survivors frequently reported subjective benefits in acute emotional coping and functionality during the attack, alongside complex post-event integration. However, claiming a definitive or established protective effect against PTSD onset overstates the evidence, which consists of retrospective, uncontrolled observational and qualitative data subject to substantial recall bias, self-selection, and confounding.
In the 1700s, many European physicians rejected citrus fruit as a treatment for scurvy, and members of the British Royal Society argued that limes and lemons might make scurvy worse.
"Many of them thought these were-- you know, there weren't that many limes and lemons in Europe at the time, right? This this was considered a South American or an African exotic plant. And so most of the physicians of the day actually rejected uh citrus fruit as a treatment for scurvy. And so as you know the story of anti-fruiters, right? There were lots of people in the British uh Royal Society that said that the that the limes and lemons may actually be making scurvy worse." (said at 1:03:40)
Historical medical literature confirms that in the 18th century, academic physicians and institutions like the British Royal Society largely ignored, dismissed, or delayed adoption of James Lind's 1747 trial demonstrating the efficacy of citrus fruit. Key figures, such as Royal Society president Sir John Pringle, heavily promoted competing theoretical treatments (including malt wort, elixir of vitriol, and purgatives) based on prevailing theories of putrefaction and humoral imbalance. However, claiming that European physicians viewed citrus as an exotic South American/African plant (citrus had been cultivated in Mediterranean Europe for centuries) or that Royal Society members formally argued citrus made scurvy worse overstates and embellishes the nature of 18th-century medical resistance, which was characterized by adherence to alternative theoretical frameworks rather than a claim that citrus actively aggravated the disease.
Fact-checked episodes
Publications
- Mystical experiences during magnesium-Ibogaine are associated with improvements in PTSD symptoms in veterans.Journal of affective disorders 2026 · CEBM Level 4
- Temporal variation of brain hemodynamics with accelerated iTBS for depression: A single-case concurrent TMS/fNIRS study.Brain stimulation 2026 · CEBM Level 4
- Stanford neuromodulation therapy for treatment-resistant depression: a randomized controlled trial confirming efficacy, and an EEG study providing insight into mechanism of action and a potentially predictive biomarker of efficacy.World psychiatry : official journal of the World Psychiatric Association (WPA) 2026 · CEBM Level 2
- Electrographic cue-reactivity co-localizes with accumbens deep brain stimulation in a case of opioid use disorder.Nature communications 2026 · CEBM Level 4
- Human orbitofrontal neural activity is linked to obsessive-compulsive behavioral dynamics.Cell 2026 · CEBM Level 4
- Accelerated recovery using magnesium ibogaine: characterizing the subjective experience of its rapid healing from neuropsychiatric disorders.Npj mental health research 2026 · CEBM Level 4
- Stereo-encephalography-guided multi-lead deep brain stimulation for treatment-refractory obsessive compulsive disorder - Study design and individualized surgical targeting approach.Journal of affective disorders 2026 · CEBM Level 5
- Neural Correlates of Ibogaine: Evidence From Functional Neuroimaging of Military Veterans.Biological psychiatry. Cognitive neuroscience and neuroimaging 2026 · CEBM Level 4
- Complexity or simplicity? A replication analysis of low heart rate as a predictor of TMS response in major depressive disorder.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2026 · CEBM Level 4
- Objective Quality Assessment for Precision Functional MRI Data.bioRxiv : the preprint server for biology 2026 · CEBM Level 5
- Increased cortical thickness and decreased brain age among special operations veterans with blast TBI after a magnesium-ibogaine protocol.iScience 2026 · CEBM Level 4
- The Use of Vagus Nerve Stimulation (VNS) in the Management of Patients with Difficult-to-Treat Major Depressive Disorder (MDD): An Expert Consensus Statement.Neuropsychiatric disease and treatment 2026 · CEBM Level 5
- Real-world evidence of SAINT® effectiveness in a heterogenous clinical population with psychiatric and medical comorbidities: A multicenter, open-label, community-based study.Journal of mood and anxiety disorders 2026 · CEBM Level 4
- Objective quality assessment for precision functional MRI data.Neuron 2026 · CEBM Level 5
- Clinical and functional connectivity changes following the stanford accelerated intelligent neuromodulation therapy (SAINT) in bipolar I depression: A pilot study.Journal of mood and anxiety disorders 2026 · CEBM Level 4
- Localizing electrophysiologic cue-reactivity within the nucleus accumbens guides deep brain stimulation for opioid use disorder.bioRxiv : the preprint server for biology 2025 · CEBM Level 4
- Towards accredited clinical training in brain stimulation: Proceedings from the brain stimulation subspecialty summits.Brain stimulation 2025 · CEBM Level 5
- Durability of clinical benefit with Stanford Neuromodulation Therapy (SNT) in treatment-resistant depression.Brain stimulation 2025 · CEBM Level 4
- Stereo-encephalography-guided multi-lead deep brain stimulation for treatment-refractory obsessive compulsive disorder - study design and individualized surgical targeting approach.medRxiv : the preprint server for health sciences 2025 · CEBM Level 5
- Interoception Biomarkers for Precision Neuromodulation.Biological psychiatry. Cognitive neuroscience and neuroimaging 2025 · CEBM Level 5
- A new flexible coil setup to measure interleaved TMS-fMRI response during accelerated iTBS.Brain stimulation 2025 · CEBM Level 5
- Trigeminal nerve stimulation as an active control condition in TMS clinical trials: Evidence from heart-brain coupling and clinical outcomes.Brain stimulation 2025 · CEBM Level 2
- Responsive deep brain stimulation guided by ventral striatal electrophysiology of obsession durably ameliorates compulsion.Neuron 2024 · CEBM Level 4
- An Avenue for Optimization of Theta Burst Stimulation Protocols? Comments on the FOUR-D Randomized Noninferiority Clinical Trial.The American journal of psychiatry 2024 · CEBM Level 5
- A preliminary randomized controlled trial of repetitive transcranial magnetic stimulation applied to the left dorsolateral prefrontal cortex in treatment seeking participants with cannabis use disorder.Drug and alcohol dependence 2024 · CEBM Level 2
- Sustained Efficacy of Stanford Neuromodulation Therapy (SNT) in Open-Label Repeated Treatment.The American journal of psychiatry 2024 · CEBM Level 4
- Magnesium-ibogaine therapy in veterans with traumatic brain injuries.Nature medicine 2024 · CEBM Level 4
- Accelerated Theta Burst Stimulation: Safety, Efficacy, and Future Advancements.Biological psychiatry 2024 · CEBM Level 5
- Pilot study of stanford neuromodulation therapy (SNT) for bipolar depression.Brain stimulation 2024 · CEBM Level 4
- Chronometric TMS-fMRI of personalized left dorsolateral prefrontal target reveals state-dependency of subgenual anterior cingulate cortex effects.Molecular psychiatry 2024 · CEBM Level 3
- Transcranial magnetic stimulation as a countermeasure for behavioral and neuropsychological risks of long-duration and deep-space missions.NPJ microgravity 2024 · CEBM Level 5
- Theta burst stimulation for depression: a systematic review and network and pairwise meta-analysis.Molecular psychiatry 2024 · CEBM Level 1
- Mechanisms of Action of TMS in the Treatment of Depression.Current topics in behavioral neurosciences 2024 · CEBM Level 5
- Should rTMS be considered a first-line treatment for major depressive episodes in adults?Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology 2024 · CEBM Level 5
- Increased anti-correlation between the left dorsolateral prefrontal cortex and the default mode network following Stanford Neuromodulation Therapy (SNT): analysis of a double-blinded, randomized, sham-controlled trial.Npj mental health research 2024 · CEBM Level 2
- Fast depressive symptoms improvement in bipolar I disorder after Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT): A two-site feasibility and safety open-label trial.Journal of affective disorders 2024 · CEBM Level 4
- Frontostriatal salience network expansion in individuals in depression.Nature 2024 · CEBM Level 3
- Strategies to mitigate scalp discomfort during repetitive transcranial magnetic stimulation.Brain stimulation 2024 · CEBM Level 5
- Early differences in lassitude predicts outcomes in Stanford Neuromodulation Therapy for difficult to treat depression.Npj mental health research 2024 · CEBM Level 3
- Difficult to Treat Depression: Focus on Approach, Algorithms, and Access.The Journal of clinical psychiatry 2024 · CEBM Level 5
- Appetitive Mapping of the Human Nucleus Accumbens.Biological psychiatry 2023 · CEBM Level 5
- Time for Brain Medicine.The Journal of neuropsychiatry and clinical neurosciences 2023 · CEBM Level 5
- Real-Time Semi-Automated and Automated Voxel Placement using fMRI Targets for Repeated Acquisition Magnetic Resonance Spectroscopy.Journal of neuroscience methods 2023 · CEBM Level 4
- Taking modern psychiatry into the metaverse: Integrating augmented, virtual, and mixed reality technologies into psychiatric care.Frontiers in digital health 2023 · CEBM Level 5
- Repetitive Transcranial Magnetic Stimulation for Treatment-Resistant Depression: Mismatch of Evidence and Insurance Coverage Policies in the United States.The Journal of clinical psychiatry 2023 · CEBM Level 5
- Targeted neurostimulation reverses a spatiotemporal biomarker of treatment-resistant depression.Proceedings of the National Academy of Sciences of the United States of America 2023 · CEBM Level 3
- No place in France for repetitive transcranial magnetic stimulation in the therapeutic armamentarium of treatment-resistant depression?Brain stimulation 2023 · CEBM Level 5
- Network effects of Stanford Neuromodulation Therapy (SNT) in treatment-resistant major depressive disorder: a randomized, controlled trial.Translational psychiatry 2023 · CEBM Level 2
- A Preliminary Investigation Of Repetitive Transcranial Magnetic Stimulation Applied To The Left Dorsolateral Prefrontal Cortex In Treatment Seeking Participants With Cannabis Use Disorder.medRxiv : the preprint server for health sciences 2023 · CEBM Level 2
- Expansion of a frontostriatal salience network in individuals with depression.bioRxiv : the preprint server for biology 2023 · CEBM Level 4
- Treatment-resistant depression: definition, prevalence, detection, management, and investigational interventions.World psychiatry : official journal of the World Psychiatric Association (WPA) 2023 · CEBM Level 5
- Concurrent TMS/fMRI reveals individual DLPFC dose-response pattern.NeuroImage 2023 · CEBM Level 4
- Transcranial Magnetic Stimulation-Induced Heart-Brain Coupling: Implications for Site Selection and Frontal Thresholding-Preliminary Findings.Biological psychiatry global open science 2023 · CEBM Level 4
- Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial.The American journal of psychiatry 2022 · CEBM Level 2
- Aberrant impulse control circuitry in obesity.Molecular psychiatry 2022 · CEBM Level 4
- Evidence for the role of the dorsal ventral lateral posterior thalamic nucleus connectivity in deep brain stimulation for Gilles de la Tourette syndrome.Journal of psychiatric research 2021 · CEBM Level 4
- Accelerated neuromodulation therapy for Obsessive-Compulsive Disorder.Brain stimulation 2021 · CEBM Level 4
- Lather, Rinse, Repeat? Breaking Repetitive Behaviors With Repetitive Stimulation.The American journal of psychiatry 2021 · CEBM Level 5
- Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.Molecular psychiatry 2021 · CEBM Level 5
- The Future of Training and Practice in Neuromodulation: An Interventional Psychiatry Perspective.Frontiers in psychiatry 2021 · CEBM Level 5
- Hypnotic predictors of agency: Responsiveness to specific suggestions in hypnosis is associated with involuntariness in fibromyalgia.Consciousness and cognition 2021 · CEBM Level 4
- Adjunctive repetitive transcranial magnetic stimulation delivers superior quality of life for focal epilepsy compared to anti-epileptic drugs: A meta-analytic utility prediction study.Brain stimulation 2020 · CEBM Level 5
- Transcranial Magnetic Stimulation Parameter Space: Wide Open for Exploration.Biological psychiatry 2020 · CEBM Level 5
- Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression.The American journal of psychiatry 2020 · CEBM Level 4
- Deep Brain Stimulation Results in Greater Symptomatic Improvement in Tourette Syndrome than Conservative Measures: A Meta-Analysis.Stereotactic and functional neurosurgery 2020 · CEBM Level 3
- Brain-Responsive Neurostimulation for Loss of Control Eating: Early Feasibility Study.Neurosurgery 2020 · CEBM Level 5
- Synchronized cervical VNS with accelerated theta burst TMS for treatment resistant depression.Brain stimulation 2020 · CEBM Level 5
- Comparative effectiveness of neuroablation and deep brain stimulation for treatment-resistant obsessive-compulsive disorder: a meta-analytic study.Journal of neurology, neurosurgery, and psychiatry 2019 · CEBM Level 3
- Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz.The American journal of psychiatry 2019 · CEBM Level 5
- Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora.The American journal of psychiatry 2019 · CEBM Level 5
- Robust clinical benefit of multi-target deep brain stimulation for treatment of Gilles de la Tourette syndrome and its comorbidities.Brain stimulation 2019 · CEBM Level 4
- Case Studies in Neuroscience: The electrophysiology of a human obsession in nucleus accumbens.Journal of neurophysiology 2019 · CEBM Level 4
- Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin.The American journal of psychiatry 2019 · CEBM Level 5
- Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect.JAMA psychiatry 2019 · CEBM Level 5
- Multimodal characterization of the human nucleus accumbens.NeuroImage 2019 · CEBM Level 5
- Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism.Molecular psychiatry 2019 · CEBM Level 2
- Optimization of epidural cortical stimulation for treatment-resistant depression.Brain stimulation 2018 · CEBM Level 5
- Closing the loop on impulsivity via nucleus accumbens delta-band activity in mice and man.Proceedings of the National Academy of Sciences of the United States of America 2018 · CEBM Level 5
- High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression.Brain : a journal of neurology 2018 · CEBM Level 4
- Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism.The American journal of psychiatry 2018 · CEBM Level 2
- Neuroversion: using electroconvulsive therapy as a bridge to deep brain stimulation implantation.Neurocase 2017 · CEBM Level 4
- It takes time to tune.Annals of translational medicine 2017 · CEBM Level 5
- Reward circuit DBS improves Parkinson's gait along with severe depression and OCD.Neurocase 2016 · CEBM Level 4
- NMDA antagonist treatment of depression.Current opinion in neurobiology 2016 · CEBM Level 5
- Five-Year Follow-Up of Bilateral Epidural Prefrontal Cortical Stimulation for Treatment-Resistant Depression.Brain stimulation 2016 · CEBM Level 4
- Beyond neural cubism: promoting a multidimensional view of brain disorders by enhancing the integration of neurology and psychiatry in education.Academic medicine : journal of the Association of American Medical Colleges 2015 · CEBM Level 5
- Oscillating Square Wave Transcranial Direct Current Stimulation (tDCS) Delivered During Slow Wave Sleep Does Not Improve Declarative Memory More Than Sham: A Randomized Sham Controlled Crossover Study.Brain stimulation 2015 · CEBM Level 2
- Interventional psychiatry: how should psychiatric educators incorporate neuromodulation into training?Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry 2014 · CEBM Level 5
- STN vs. GPi Deep Brain Stimulation: Translating the Rematch into Clinical Practice.Movement disorders clinical practice 2014 · CEBM Level 5
- Interventional psychiatry: why now?The Journal of clinical psychiatry 2014 · CEBM Level 5
- Adjunctive triple chronotherapy (combined total sleep deprivation, sleep phase advance, and bright light therapy) rapidly improves mood and suicidality in suicidal depressed inpatients: an open label pilot study.Journal of psychiatric research 2014 · CEBM Level 4
- Role of functional imaging in the development and refinement of invasive neuromodulation for psychiatric disorders.World journal of radiology 2014 · CEBM Level 5
- Unique case of "post-lumbar puncture headache".Headache 2013 · CEBM Level 4
- Incidence of sport-related traumatic brain injury and risk factors of severity: a population-based epidemiologic study.Annals of epidemiology 2013 · CEBM Level 3
- Deep brain stimulation (DBS) at the interface of neurology and psychiatry.The Journal of clinical investigation 2013 · CEBM Level 5
- An overview of sports concussion.Journal of the South Carolina Medical Association (1975) 2013 · CEBM Level 5
- Sports-related concussions.Pediatric emergency care 2012 · CEBM Level 5
- High school coaches perceptions of physicians' role in the assessment and management of sports-related concussive injury.Frontiers in neurology 2012 · CEBM Level 4
- Diagnosis, treatment, and long-term outcomes of late-onset (type III) multiple acyl-CoA dehydrogenase deficiency.Journal of child neurology 2010 · CEBM Level 4
- Relapse rates with long-term antidepressant drug therapy: a meta-analysis.Human psychopharmacology 2009 · CEBM Level 1
- Accelerated Repetitive Transcranial Magnetic Stimulation to Treat Major Depression: The Past, Present, and Future.Harvard review of psychiatry · CEBM Level 5